Green tea polyphenols as a natural tumour cell proteasome inhibitor

被引：45

作者：

Dou Q.P. ^{[1
,2
]}

Landis-Piwowar K.R. ^{[1
,2
]}

Chen D. ^{[1
,2
]}

Huo C. ^{[3
,4
]}

Wan S.B. ^{[3
,5
]}

Chan T.H. ^{[3
,4
]}

机构：

[1] Prevention Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit

[2] Department of Pathology, School of Medicine, Wayne State University, Detroit, MI 48201

[3] Department of Applied Biology and Chemical Technology, Polytechnic University of Hong Kong, Hung Hom

[4] Department of Chemistry, McGill University, Montreal, QC

[5] Key Laboratory of Marine Drug, Medical College, Ocean University of China, Qingdao

来源：

Inflammopharmacology | 2008年 / 16卷 / 5期

基金：

美国国家卫生研究院; 加拿大自然科学与工程研究理事会;

关键词：

Cancer prevention; Chemotherapy; Methylation; Molecular target; Prodrug; Proteasome inhibitors; Tea polyphenols;

D O I：

10.1007/s10787-008-8017-8

中图分类号：

学科分类号：

摘要：

The cancer-preventive effects of green tea and its main constituent (-)-epigallocatechin gallate [(-)-EGCG] are widely supported by results from epidemiological, cell culture, animal and clinical studies although the molecular target has not been well defined. We previously reported that ester bond-containing tea polyphenols, e. g. (-)-EGCG, and their synthetic analogs potently and specifically inhibited the proteasomal activity. Subsequently, we further demonstrated that methylation on green tea polyphenols under physiological conditions decreased their proteasome-inhibitory activity, contributing to decreased cancer-preventive effects of tea consumption. Since (-)-EGCG is unstable under physiological conditions, we also developed the peracetate-protected or prodrug form of (-)-EGCG, Pro-EGCG (1), and shown that Pro-EGCG (1) increases the bioavailability, stability, and proteasome-inhibitory and anticancer activities of (-)-EGCG in human breast cancer cells and xenografts, suggesting its potential use for cancer prevention and treatment. © 2008 Birkhäuser Verlag.

引用

页码：208 / 212

页数：4

共 28 条

[1]

Adams J., Development of the proteasome inhibitor PS-341, Oncologist, 7, pp. 9-16, (2002)

[2]

An B., Goldfarb R.H., Siman R., Dou Q.P., Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts, Cell Death Differ, 5, pp. 1062-1075, (1998)

[3]

Catley L., Tai Y.T., Chauhan D., Anderson K.C., Perspectives for combination therapy to overcome drug-resistant multiple myeloma, Drug Resist. Updates, 8, pp. 205-218, (2005)

[4]

Ciechanover A., The ubiquitin-proteasome pathway: On protein death and cell life, EMBO J, 17, pp. 7151-7160, (1998)

[5]

Ciechanover A., Orian A., Schwartz A.L., Ubiquitin-mediated proteolysis: Biological regulation via destruction, Bioessays, 22, pp. 442-451, (2000)

[6]

Dou Q.P., Goldfarb R.H., Bortezomib (millennium pharmaceuticals), IDrugs, 5, pp. 828-834, (2002)

[7]

Fujiki H., Two stages of cancer prevention with green tea, J Cancer Res Clin Oncol, 125, pp. 589-597, (1999)

[8]

Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., Et al., Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma, J. Clin. Oncol, 23, pp. 667-675, (2005)

[9]

Groll M., Heinemeyer W., Jager S., Ullrich T., Bochtler M., Wolf D.H., Huber R., The catalytic sites of 20S proteasomes and their role in subunit maturation: A mutational and crystallographic study, Proc. Natl. Acad. Sci. (USA), 96, pp. 10976-10983, (1999)

[10]

Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., Anderson K.C., The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res, 61, pp. 3071-3076, (2001)

← 1 2 3 →